153 related articles for article (PubMed ID: 28167571)
1. Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
Walko CM; Aubert RE; La-Beck NM; Clore G; Herrera V; Kourlas H; Epstein RS; McLeod HL
Oncologist; 2017 Feb; 22(2):208-212. PubMed ID: 28167571
[TBL] [Abstract][Full Text] [Related]
2. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Feldt S; Schüssel K; Quinzler R; Franzmann A; Czeche S; Ludwig WD; Schulz M
Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Clemons J; Gao D; Naam M; Breaker K; Garfield D; Flaig TW
Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
[TBL] [Abstract][Full Text] [Related]
4. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Shu M; Zai X; Zhang B; Wang R; Lin Z
PLoS One; 2016; 11(1):e0147048. PubMed ID: 26784451
[TBL] [Abstract][Full Text] [Related]
5. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
Calvani N; Morelli F; Leo S; Orlando L; Lombardi L; Gnoni A; Cinefra M; Maiello E; Lorusso V; Cinieri S
Med Oncol; 2012 Sep; 29(3):1908-13. PubMed ID: 21858552
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
7. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Jang S; Zheng C; Tsai HT; Fu AZ; Barac A; Atkins MB; Freedman AN; Minasian L; Potosky AL
Cancer; 2016 Jan; 122(1):124-30. PubMed ID: 26439451
[TBL] [Abstract][Full Text] [Related]
9. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
Chin J Cancer; 2017 Aug; 36(1):64. PubMed ID: 28789709
[TBL] [Abstract][Full Text] [Related]
13. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
14. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
[TBL] [Abstract][Full Text] [Related]
15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
16. Hypothyroidism during treatment with tyrosine kinase inhibitors.
Zygulska AL; Krzemieniecki K; Sowa-Staszczak A
Endokrynol Pol; 2012; 63(4):302-6. PubMed ID: 22933166
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
18. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
19. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
20. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
Koldenhof JJ; Witteveen PO; de Vos R; Walraven M; Tillier CN; Verheul HM; Teunissen SC
Support Care Cancer; 2014 Sep; 22(9):2371-80. PubMed ID: 24687539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]